DM
NKTR icon

Deerfield Management’s Nektar Therapeutics NKTR Stock Holding History

Deerfield Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,040
Closed -$502K – 132
2015
Q1 		$502K Buy
+3,040
New +$625K 0.02% 115
2013
Q3 		– Sell
-195,983
Closed -$34M – 127
2013
Q2 		$34M Buy
+195,983
New +$30.1M 1.6% 21

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Deerfield Management's NKTR Position: Q2 2015 in Review

Deerfield Management sold out of Nektar Therapeutics (NKTR) in Q2 2015, closing a stake of 3,040 shares — an estimated $502K sold.

Deerfield Management first reported a position in NKTR in Q2 2013 and held it in 2 quarters. The position peaked at $34M in Q2 2013. 181 funds tracked by Wall St. Rank hold NKTR as of Q2 2015.

  • Deerfield Management reported no remaining Nektar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Deerfield Management sold 3,040 Nektar Therapeutics shares in Q2 2015, an estimated $502K.
  • Deerfield Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 2 quarters.
  • Deerfield Management's Nektar Therapeutics position peaked at $34M in Q2 2013.
  • 181 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2015.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.